secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001213900-26-033507
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Yehuda Eliya term expires, leaves Raphael board effective Dec 31, 2025
-------------------------------------------------------------------------------

- Dr. Yehuda Eliya's board term expired Dec 31, 2025; ceased serving as director.
- Departure not related to any disagreement with company operations, policies, or practices.
- No replacement director announced as of filing date March 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026033507/0001213900-26-033507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390026033507/ea0283251-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-033507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer